Clinical

Videos

CancerNetwork® spoke with Albert H. Kim, MD, PhD, about a new Brain Tumor Center at Siteman, for which he is the inaugural director.  

Medical World News® Inside the Practice: CancerNetwork® and Albert H. Kim, MD, PhD, on Treating Brain Tumor Malignancies at the Siteman Cancer Center

Articles

A durable clinical benefit was seen from the dual inhibition of the MAPK pathway using BRAF and MEK inhibitors dabrafenib and trametinib, respectively, to treat patients with BRAF V600E mutant low- and high-grade glioma.

Clinical Benefit Observed With Dabrafenib Plus Trametinib Combo for Glioma Subtypes

Germline variants in cancer predisposition genes were associated with worse event-free and overall survival in patients with neuroblastoma.

Pathogenic Germline Variants Correlate With Worse Survival Outcomes in Neuroblastoma

ERC-USA announced that the FDA recommended the early termination of a phase 2 clinical trial of ERC1671 to treat patients with recurrent or progressive glioblastoma and pursue a randomized confirmatory phase 3 trial.

FDA Recommends Early Termination of Phase 2 Trial Investigating ERC1671 to Treat Glioblastoma

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promoter status who have completed initial radiation with concomitant temozolomide.

FDA Grants Fast Track Designation to Paxalisib for Patients with Glioblastoma

Though the combination of bevacizumab and trebananib was found to be well tolerated, it did not significantly improve survival outcomes for patients with recurrent glioblastoma over bevacizumab alone.

Phase II Trial of Bevacizumab/Trebananib Combo Fails to Demonstrate Improvements

A population-based analysis found that racial and ethnic disparities in childhood central nervous system tumor survival seem to have their roots at least partially in post-diagnosis factors, possibly due to the lack of access to high quality care, leading to poorer overall outcomes.

Racial/Ethnic Disparities in Pediatric Patients with Brain Cancer 

The biologics license application was supported by findings from a global, randomized, controlled phase III clinical trial, evaluating the efficacy, safety, and immunogenicity of MYL-1402O versus bevacizumab.

FDA Accepts BLA for Proposed Biosimilar to Bevacizumab, MYL-1402O

The key to predicting when liquid biopsy would produce clinically actionable information is the ability to image the blood brain barrier and macrophages, according to researchers.

Brain Imaging May Predict When Liquid Biopsy Would Produce Clinically Actionable Information

The results presented in this study indicated that neurosurgeons may need to change how they approach tumor removal and, when safe, include non-contrast-enhancing tumor during resection to achieve maximal resection.

Brain Cancer | Topics